Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men

What Was Tested

This randomized controlled trial paper looks at Peptide YY.

To investigate the effects of PYY administration on the reproductive axis in healthy young men.

Why It Was Studied

Central and peripheral administration of peptide YY (PYY) has potent anorectic effects, and PYY analogs are under development as antiobesity treatments.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

Eighteen healthy eugonadal men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m2).

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether Peptide YY was given.

Some participants received a placebo instead of Peptide YY, giving a reference point.

Each person switched between Peptide YY and the comparison at some point, usually with a gap in between.

Single-blind, randomized, placebo-controlled crossover study.

Clinical Research Facility, Imperial College Healthcare NHS Trust.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Follicle Stimulating Hormone, Healthy Volunteers, Hypothalamo-Hypophyseal System, Luteinizing Hormone, Peptide YY and Prognosis.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Peptide YY.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Peptide YY compound page, all human trials.